Stem cell commercialization expert Dr. Jennifer Moody appointed Chief Operating Officer beginning October 7th, 2019.
Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.
Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.
Morphocell Technologies signs exclusive license for the commercialisation of innovative stem cell-derived Encapsulated Liver Tissue technology.